journal article·2026-04-01

Disrupting the Fortress: A Biomimetic Nano-Dual-Sensitizer Remodels Tumor Microenvironment via Dual HIF-1α Inhibition for Robust Photo-Immunotherapy

Xin Zhang, Zutong Cui, Wenming Liang, Zihan Zhang, Jianming Sun, Liming Gao, Ming Shi, Zhiwei Liu, Kun Li, Jian Li

ACS Applied Materials & Interfaces· Volume 18· Issue 12
Publisher page

Abstract

Phototherapy not only targets tumor cells for destruction but also triggers immunogenic cell death (ICD), thereby activating systemic immunity. Traditional photothermal therapy (PTT), however, damages adjacent normal tissues, and photodynamic therapy (PDT) creates severe hypoxia within tumor tissues, which promotes immune evasion and reduces the effectiveness of immunotherapy. In this study, we developed a biomimetic nanomodulators-cell membrane-coated gambogic acid/indocyanine green micelles loaded with HIF-1α siRNA (CM-IGM/siRNA) to achieve mild photothermal therapy (mPTT), enhance photodynamic therapy (PDT), and modulate the tumor microenvironment (TME). This platform utilizes gambogic acid (GA) to inhibit HSP90 expression and synergizes with HIF-1α siRNA to suppress HIF-1α expression, thereby ameliorating hypoxic and immunosuppressive TME. HSP90 inhibition further reduces tumor cell thermotolerance, enabling effective tumor cell ablation at mild hyperthermia temperatures (42-45 °C) characteristic of mPTT. Furthermore, we found that π-π stacking of GA with indocyanine green (ICG) enhances ICG photostability and boosts reactive oxygen species (ROS) generation. The elevated ROS production significantly improves PDT efficacy and, in combination with mPTT, potentiates the ICD of tumor cells. Overall, this strategy offers a significant advancement in cancer immunotherapy by improving the tumor microenvironment and enhancing immune activation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Hebei Key Laboratory of Applied Chemistry, Hebei Key Laboratory of Nano-biotechnology, Hebei Key Laboratory of Heavy Metal Deep-Remediation in Water and Resource Reuse

Yanshan University

The First Hospital of Qinhuangdao

Funding

Natural Science Foundation of Hebei Province

References (54)

Show source-provided references
1. 10.1016/j.jconrel.2023.06.00910.1016/j.jconrel.2023.06.009 ↗
2. 10.1016/j.biomaterials.2022.12142510.1016/j.biomaterials.2022.121425 ↗
3. 10.1021/acsnano.3c0089110.1021/acsnano.3c00891 ↗
4. 10.1002/adma.20200777810.1002/adma.202007778 ↗
5. 10.1002/smll.20210600010.1002/smll.202106000 ↗
6. 10.1002/adma.20231029810.1002/adma.202310298 ↗
7. 10.1002/adma.20230953410.1002/adma.202309534 ↗
8. 10.1021/acsami.3c0987310.1021/acsami.3c09873 ↗
9. 10.1016/j.canlet.2019.04.03710.1016/j.canlet.2019.04.037 ↗
10. 10.1186/s12951-023-02111-x10.1186/s12951-023-02111-x ↗
11. 10.1021/acsami.6b1315010.1021/acsami.6b13150 ↗
12. 10.1016/j.cclet.2025.11113310.1016/j.cclet.2025.111133 ↗
13. 10.1021/acsami.3c1255310.1021/acsami.3c12553 ↗
14. 10.1016/j.mtbio.2023.10076510.1016/j.mtbio.2023.100765 ↗
15. 10.1016/j.biomaterials.2019.11931210.1016/j.biomaterials.2019.119312 ↗
16. 10.1002/adma.20210397810.1002/adma.202103978 ↗
17. 10.1016/j.cclet.2025.11119510.1016/j.cclet.2025.111195 ↗
18. 10.1002/adma.20240272010.1002/adma.202402720 ↗
19. 10.1016/j.mattod.2024.07.01210.1016/j.mattod.2024.07.012 ↗
20. 10.1016/j.lfs.2023.12165510.1016/j.lfs.2023.121655 ↗
21. 10.3390/ijms2303174510.3390/ijms23031745 ↗
22. 10.1016/j.biomaterials.2022.12180110.1016/j.biomaterials.2022.121801 ↗
23. 10.1016/j.oraloncology.2015.08.01110.1016/j.oraloncology.2015.08.011 ↗
24. 10.1158/0008-5472.CAN-13-099210.1158/0008-5472.CAN-13-0992 ↗
25. 10.1016/j.colsurfb.2020.11110410.1016/j.colsurfb.2020.111104 ↗
26. 10.1016/j.isci.2024.11053310.1016/j.isci.2024.110533 ↗
27. 10.3389/fonc.2022.98749110.3389/fonc.2022.987491 ↗
28. 10.1016/j.bioadv.2022.21315310.1016/j.bioadv.2022.213153 ↗
29. 10.1016/j.ajps.2021.10.00110.1016/j.ajps.2021.10.001 ↗
30. 10.1016/j.jcis.2023.09.02410.1016/j.jcis.2023.09.024 ↗
31. 10.2147/IJN.S40502010.2147/IJN.S405020 ↗
32. 10.1021/acs.nanolett.4c0376610.1021/acs.nanolett.4c03766 ↗
33. 10.1021/acsami.4c0419610.1021/acsami.4c04196 ↗
34. 10.1016/j.jcis.2024.05.14910.1016/j.jcis.2024.05.149 ↗
35. 10.1016/j.bioactmat.2021.07.01410.1016/j.bioactmat.2021.07.014 ↗
36. 10.2147/IJN.S27764510.2147/IJN.S277645 ↗
37. 10.1016/j.colsurfb.2025.11518310.1016/j.colsurfb.2025.115183 ↗
38. 10.1016/j.apsb.2025.04.00710.1016/j.apsb.2025.04.007 ↗
39. 10.1038/s41590-022-01132-210.1038/s41590-022-01132-2 ↗
40. 10.1021/acsmaterialslett.3c0067610.1021/acsmaterialslett.3c00676 ↗
41. 10.1002/smll.20230403210.1002/smll.202304032 ↗
42. 10.1016/j.jconrel.2022.10.04610.1016/j.jconrel.2022.10.046 ↗
43. 10.1158/1535-7163.MCT-24-002410.1158/1535-7163.MCT-24-0024 ↗
44. 10.1016/j.actbio.2022.03.02410.1016/j.actbio.2022.03.024 ↗
45. 10.2147/IJN.S20864910.2147/IJN.S208649 ↗
46. 10.3390/pharmaceutics1604056610.3390/pharmaceutics16040566 ↗
47. 10.1021/acsami.3c1256010.1021/acsami.3c12560 ↗
48. 10.1038/s41571-022-00699-x10.1038/s41571-022-00699-x ↗
49. 10.1016/j.canlet.2023.21610610.1016/j.canlet.2023.216106 ↗
50. 10.1021/acsnano.3c0301310.1021/acsnano.3c03013 ↗
51. 10.1016/j.jcis.2023.08.10910.1016/j.jcis.2023.08.109 ↗
52. 10.1016/j.colsurfb.2024.11425410.1016/j.colsurfb.2024.114254 ↗
53. 10.1021/acsnano.4c1628010.1021/acsnano.4c16280 ↗
54. 10.1038/s41419-022-05373-910.1038/s41419-022-05373-9 ↗